17p Deletion in acute myeloid leukemia and myelodysplastic syndrome. Analysis of breakpoints and deleted segments by fluorescence in situ.

Recently, we and other groups reported in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) a strong correlation between cytogenetic rearrangements leading to 17p deletion, a typical form of dysgranulopoiesis combining pseudo-Pelger-Huët hypolobulation and small vacuoles in neutrophils, and p53 mutation. To gain further insight into this "17p-syndrome," we studied 17 cases of AML and MDS with 17p deletion by whole chromosome painting (WCP) and fluorescence in situ hybridization (FISH) with probes spanning the 17p arm, including a p53 gene probe. Cytogenetically, 15 patients had unbalanced translocation between chromosome 17 and another chromosome (chromosome 5 in nine cases and unidentified chromosome -add 17p- in three cases), one patient had monosomy 17, and one had i(17q). All rearrangements appeared to result in 17p deletion. Sixteen patients had additional cytogenetic rearrangements. WCP analysis confirmed the cytogenetic interpretation in all cases and identified one of the cases of add 17p as a t(17;22). WCP also identified chromosome 17 material on a marker or ring chromosome in two cases of t(5;17). FISH analysis with 17p markers made in 16 cases showed no deletion of the 17p markers studied in the last two patients, who had no typical dysgranulopoiesis; p53 mutation analysis in one of them was negative. In the 14 other cases, FISH showed a 17p deletion of variable extent but that always included deletion of the p53 gene. All 14 patients had typical dysgranulopoiesis, and all but one had p53 mutation and/or overexpression. These findings reinforce the morphologic, cytogenetic, and molecular correlation found in the 17p-syndrome and suggest a pathogenetic role for inactivation of tumor suppressor gene(s) located in 17p, especially the p53 gene.

[1]  C. Mecucci,et al.  Cytogenetics of myelodysplastic syndromes. , 1999, Forum.

[2]  G. Flandrin,et al.  The 17p-syndrome: a distinct myelodysplastic syndrome entity? , 1997, Leukemia & lymphoma.

[3]  D. Le Paslier,et al.  A 3.1-Mb YAC contig within the Werner syndrome region, on the short arm of human chromosome 8. , 1996, Cytogenetics and cell genetics.

[4]  P. Rigault,et al.  A YAC contig map of the human genome. , 1995, Nature.

[5]  E. Wattel,et al.  Myelodysplastic syndromes and acute myeloid leukemia with 17p deletion. An entity characterized by specific dysgranulopoïesis and a high incidence of P53 mutations. , 1995, Leukemia.

[6]  B. Quesnel,et al.  p53 Mutations Are Associated With Resistance to Chemotherapy and Short Survival in Hematologic Malignancies , 1994 .

[7]  B. Quesnel,et al.  Detection of p53 mutations in hematological malignancies: comparison between immunocytochemistry and DNA analysis. , 1994, Leukemia.

[8]  R. Berger,et al.  Whole arm translocation t(17;18): a non-random abnormality of myeloid cell proliferation. , 1993, Leukemia.

[9]  D. Longo,et al.  p53 mutation is associated with progression in follicular lymphomas. , 1993, Blood.

[10]  G. Janković,et al.  Two karyotypically unrelated clones with the t(5;17) and deletion of 5q in myelodysplastic syndrome. , 1992, Cancer genetics and cytogenetics.

[11]  G. Mufti,et al.  A guide to risk assessment in the primary myelodysplastic syndrome. , 1992, Hematology/oncology clinics of North America.

[12]  T Takahashi,et al.  Wild-type but not mutant p53 suppresses the growth of human lung cancer cells bearing multiple genetic lesions. , 1992, Cancer research.

[13]  P. Nowell.  Chromosome abnormalities in myelodysplastic syndromes. , 1992, Seminars in oncology.

[14]  R. Berger,et al.  Mutations in the p53 gene in myelodysplastic syndromes. , 1991, Oncogene.

[15]  P. Nowell,et al.  Therapy-related myelodysplastic syndrome and acute myeloid leukemia in children: correlation between chromosomal abnormalities and prior therapy. , 1991, Blood.

[16]  R. Berger,et al.  P53 gene mutations in acute myeloid leukemia with 17p monosomy. , 1991, Blood.

[17]  J. Pedersen‐Bjergaard,et al.  Balanced translocations involving chromosome bands 11q23 and 21q22 are highly characteristic of myelodysplasia and leukemia following therapy with cytostatic agents targeting at DNA-topoisomerase II [letter] , 1991 .

[18]  N. Galjart,et al.  The gene encoding human protective protein (PPGB) is on chromosome 20. , 1991, Genomics.

[19]  M. Bar‐eli,et al.  The spectrum of molecular alterations in the evolution of chronic myelocytic leukemia. , 1991, The Journal of clinical investigation.

[20]  J. Pedersen‐Bjergaard,et al.  Balanced translocations involving chromosome bands 11q23 and 21q22 are highly characteristic of myelodysplasia and leukemia following therapy with cytostatic agents targeting at DNA-topoisomerase II. , 1991, Blood.

[21]  P. Fenaux,et al.  Translocations (5;17) and (7;17) in patients with de novo or therapy-related myelodysplastic syndromes or acute nonlymphocytic leukemia. A possible association with acquired pseudo-Pelger-Huët anomaly and small vacuolated granulocytes. , 1990, Cancer genetics and cytogenetics.

[22]  H. Preisler,et al.  Cytogenetic study of maturing granulocytes in bone marrow of patients with acute myelogenous leukemia. , 1990, Leukemia.

[23]  L. Stuppia,et al.  Karyotypic changes identified by HaeIII restriction endonuclease banding in a patient with M2 acute non‐lymphoblastic leukemia , 1990, Genes, chromosomes & cancer.

[24]  J. Rowley,et al.  Clinical-cytogenetic correlations in myelodysplasia (preleukemia). , 1989, Cancer genetics and cytogenetics.

[25]  F. Ajmar,et al.  Correlation between acquired pseudo-Pelger-Huet anomaly and involvement of chromosome 17 in chronic myeloid leukemia. , 1987, Cancer genetics and cytogenetics.

[26]  F. Mitelman,et al.  Chromosome abnormalities in the myelodysplastic syndromes. , 1986, Clinics in haematology.

[27]  R. Larson,et al.  Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no. 5 and 7. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  G. Tricot,et al.  The 5q-anomaly. , 1985, Cancer genetics and cytogenetics.

[29]  H. Gralnick,et al.  Proposals for the classification of the myelodysplastic syndromes , 1982, British journal of haematology.

[30]  Iscn.  International System for Human Cytogenetic Nomenclature , 1978 .